Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)

Next Previous
Trial Profile

Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms PASART-2

Most Recent Events

  • 15 Jan 2025 Results (n=34) assessing long-term follow-up data from PASART-1 and PASART-2 studies and comparing these data during the same time period with the Netherlands Cancer Registry (IKNL), published in the Acta Oncologica
  • 01 Dec 2021 According to results published in the Acta Oncologica, after an interim analysis, a protocol was amended to reduce dose of radiotherapy to 36 Gy in 18 fractions of once daily 2 Gy for 5 days a week to reduce the risk of acute post operative wound complications
  • 01 Dec 2021 Primary endpoint of pathological near complete remission of the resected specimen which has been treated with radiotherapy has not been met, according to results published in the Acta Oncologica.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top